Acepodia is developing potent, off-the-shelf targeted cancer cell therapies that unlock the immune system’s ability to fight both solid tumors and hematological malignancies.
Antibody-Cell Conjugation (ACC) technology uses live-cell compatible chemistry to link any tumor-targeting antibody to the surface of human immune cells. This powerful, new approach to cell therapy development has the potential to dramatically enhance the ability of oNK cells and NK-like gamma delta T cells to recognize and engage the tumor by unlocking multiple receptor signaling pathways. This could potentially allow ACC-oNK therapies to overcome the challenges that have prevented cell therapies from effectively targeting solid tumors.
In order to develop the most effective immunotherapies possible, Acepodia combines its ACC technology with both of its proprietary off-the-shelf NK (oNK) cells and NK-like gamma delta (NKγδ) T cells which are allogeneic, and specially selected for enhanced tumor engagement. ACC allows for any antibody to be conjugated to the stimulatory surface receptors of these immune cells to yield the additive effect of superior tumor targeting to its already potent and off-the-shelf biologic drug payloads.
PROMISING PIPELINE OF CELL THERAPIES